Please login to the form below

Not currently logged in
Email:
Password:

Human Genome Sciences rejects GSK's $2.59bn takeover bid

GSK’s partner in Benlysta to seek alternative offers

Human Genome Sciences rejects GSK's $2.59bn takeover bid

Human Genome Sciences (HGS) is seeking other offers after rejecting a $13 per share unsolicited bid yesterday from longstanding partner GlaxoSmithKline (GSK), which valued the firm at $2.59bn.

GSK's offer is an 81 per cent premium to HGS' closing price of $7.17 the day before the bid, but the stock doubled yesterday to $14.37, albeit still below its 52-week high of around $30.

In a statement issued swiftly after GSK's bid was announced, HGS said the offer does not reflect "the value inherent in the company", adding that it has retained Goldman Sachs and Credit Suisse to try to find "strategic alternatives", including a possible sale of the company.

US-based HGS has worked with GSK for years on a number of drugs, including lupus erythematosus treatment Benlysta (belimumab) which was approved in March 2011 and was HGS' first commercialised drug, with sales of around $50m by the end of the last year.

Analysts have suggested Benlysta could make as much as $4bn in annual sales, but in the meantime HGS is still in cash burn mode, posting a $381m loss last year.

The two companies are also working together on developmental-stage drugs, notably Lp-PLA2 inhibitor darapladib which is in phase III testing for acute coronary syndrome and albiglutide, currently in phase III development for the treatment of type 2 diabetes.

"HGS has requested additional information regarding investigational products in GSK's clinical pipeline to which HGS has substantial financial rights," said the US firm.

GSK appeared to be taken aback by the abruptness of HGS' rejection of its offer, with CEO Andrew Witty saying he was disappointed that the bid had been dismissed without negotiation.

"Having worked together with HGS for nearly 20 years, we believe there is clear strategic and financial logic to this combination for both companies and our respective shareholders," Witty said, adding that GSK expected to achieve at least $200m in cost synergies by 2015.

HGS may be hoping to start a bidding war for its business, and has invited GSK to participate in its "exploration of strategic alternatives". Industry observers have expressed doubt whether other bidders will some forward however, given the close ties between HGS and GSK.

20th April 2012

Share

Error 404 Not Found

HTTP ERROR: 404

Problem accessing /search/admin/. Reason:

    Not Found


Powered by Jetty://

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
LEC

Welcome to our world. We specialise in creating, launching and revitalising brands all over the world. We blend science, creative,...

Latest intelligence

blog-icon_build_your_argumentation.png
Build your e-detailing argumentation
We’ve written a number of posts recently giving insights into the Anthill method for structuring e-detailing & CLM presentations. To help you overview, we’ve put these argumentation posts together....
Growing influence of pharmacists in the sale of Rx and OTC medicines
Find out how the changes within pharmacy have affected their influence over the sales of RX and OTC medicines in this whitepaper....
Drivers of 2014′s Soaring Drug Approvals
The FDA & EMA approved a chart-topping number of new drugs in 2014. Read more in our White Paper about the responsibility this growing approval success will put on future...